BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.
Evelina MieleLuana AbballeGian Paolo SpinelliZein Mersini BesharatGiuseppina CatanzaroMartina ChiacchiariniAlessandra VaccaAgnese PoCarlo CapalboElisabetta FerrettiPublished in: BMC cancer (2020)
Our findings support the importance of ErbB2 evaluation in BRAF-mutated CRC patients and its role as a positive predictor factor of response to BRAFi/ErbBi combination.